Abstract
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels play important roles both in the control of heart rate and neuronal excitability. HCN channels open on hyperpolarization voltage, permeate to potassium and sodium, and generate an inward current, which is modulated by intracellular cAMP. HCN channels have been reported to involve in various human diseases, including heart failure, pain and epilepsy with datas from mutagenesis, transgenic mice and pharmacological studies. As a result, HCN channels may offer excellent drug development opportunities for novel analgestic, bradycardic and anticonvulsant drugs. Ivabradine is the first HCN channel inhibitor being clinically approved in 2005 for the treatment of chronic stable angina pectoris and heart failure. This review will summarize the structure and function of HCN channels. Further, we will discuss recent advances concerning the identification and action mechanism of reported HCN channel inhibitors.
Keywords: Arrhythmia, channel inhibitors, epilepsy, HCN channels, heart failure, ivabradine, pain
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:HCN Channel as Therapeutic Targets for Heart Failure and Pain
Volume: 16 Issue: 16
Author(s): Ying Cao, Jianxin Pang and Pingzheng Zhou
Affiliation:
Keywords: Arrhythmia, channel inhibitors, epilepsy, HCN channels, heart failure, ivabradine, pain
Abstract: Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels play important roles both in the control of heart rate and neuronal excitability. HCN channels open on hyperpolarization voltage, permeate to potassium and sodium, and generate an inward current, which is modulated by intracellular cAMP. HCN channels have been reported to involve in various human diseases, including heart failure, pain and epilepsy with datas from mutagenesis, transgenic mice and pharmacological studies. As a result, HCN channels may offer excellent drug development opportunities for novel analgestic, bradycardic and anticonvulsant drugs. Ivabradine is the first HCN channel inhibitor being clinically approved in 2005 for the treatment of chronic stable angina pectoris and heart failure. This review will summarize the structure and function of HCN channels. Further, we will discuss recent advances concerning the identification and action mechanism of reported HCN channel inhibitors.
Export Options
About this article
Cite this article as:
Cao Ying, Pang Jianxin and Zhou Pingzheng, HCN Channel as Therapeutic Targets for Heart Failure and Pain, Current Topics in Medicinal Chemistry 2016; 16 (16) . https://dx.doi.org/10.2174/1568026616666151215104058
DOI https://dx.doi.org/10.2174/1568026616666151215104058 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry The Usefulness of Phalangeal Quantitative Ultrasound in the Assessment of Skeletal Status in Children and Adolescents
Current Medical Imaging Lexical Characterisation of Bio-Ontologies by the Inspection of Regularities in Labels
Current Bioinformatics Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA Acid-Sensing Ion Channels Structural Aspects, Pathophysiological Importance and Experimental Mutational Data Available Across Various Species to Target Human ASIC1
Current Drug Targets Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry Neurophysiological Alterations in the Prepsychotic Phases
Current Pharmaceutical Design Caring for Children with Medical Complexity: Definitions, Challenges and Solutions
Current Pediatric Reviews Are Raw Scores on Memory Tests Better than Age- and Education- Adjusted Scores for Predicting Progression from Amnesic Mild Cognitive Impairment to Alzheimer Disease ?
Current Alzheimer Research Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Aquaporins and Roles in Brain Health and Brain Injury
Mini-Reviews in Medicinal Chemistry Preface:
Current Topics in Medicinal Chemistry Editorial [Hot Topic: New Mechanisms of Neuronal Injury and Neuroprotection (Guest Editor: Weihai Ying)]
Current Drug Targets Intraoperative Seizures: Anesthetic and Antiepileptic Drugs
Current Pharmaceutical Design Controlled Somatic and Germline Copy Number Variation in the Mouse Model
Current Genomics Nerolidol and its Pharmacological Application in Treating Neurodegenerative Diseases: A Review
Recent Patents on Biotechnology Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Current Vascular Pharmacology Serum Thiol-Disulphide Levels in Epileptic Pediatric Patients
Combinatorial Chemistry & High Throughput Screening